BioTime, Inc. to Present at Three Investor Conferences in February
February 01 2016 - 1:17PM
Business Wire
BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative
medicine company with a focus on pluripotent stem cell technology,
announced today that it will present at the following three
investor conferences in February:
- 18th Annual BIO CEO & Investor
Conference in New York City on Tuesday, February 9 at 2:00 p.m.
ET
- Source Capital Group’s 2016 Disruptive
Growth and Healthcare Conference in New York City on Wednesday,
February 10, 2016 at 8:30 a.m. ET
- Gelbart-Kahana Biomed Conference in Tel
Aviv, Israel on Wednesday, February 10, 2016.
Additionally, Michael D. West, Ph.D., co-Chief Executive
Officer, one of the pioneers of the regenerative medicine industry,
will participate in the Regenerative Medicine panel at the Source
Capital Group’s Disruptive Growth and Healthcare Conference on
Wednesday, February 10, 2016 at 1:30 p.m. ET.
About BioTime
BioTime, Inc., a pioneer in regenerative medicine, is a
clinical-stage biotechnology company. BioTime and its
subsidiaries are leveraging their industry-leading experience in
pluripotent stem cell technology and a broad intellectual property
portfolio to facilitate the development and use of cell-based
therapies and gene marker-based molecular diagnostics for major
diseases and degenerative conditions for which there presently are
no cures. The lead clinical programs of BioTime and its
subsidiaries include OpRegen®, currently in a Phase I/IIa
trial for the treatment of the dry form of age-related macular
degeneration; AST-OPC1, currently in a Phase I/IIa trial for
spinal cord injuries; Renevia™, currently in a pivotal trial
in Europe as an injectable matrix for the engraftment of
transplanted cells to treat HIV-related lipoatrophy;
and cancer diagnostics, nearing the completion of initial
clinical studies for the detection of lung, bladder, and breast
cancers. AST-VAC2, a cancer vaccine, is in the pre-clinical
trial stage.
BioTime’s subsidiaries include the publicly traded Asterias
Biotherapeutics, Inc., developing pluripotent stem cell-based
therapies in neurology and oncology, including AST-OPC1 and
AST-VAC2; Cell Cure Neurosciences Ltd., developing stem cell-based
therapies for retinal and neurological disorders, including
OpRegen®; publicly traded OncoCyte Corporation, developing cancer
diagnostics; LifeMap Sciences, Inc., developing and marketing an
integrated online database resource for biomedical and stem cell
research; LifeMap Solutions, Inc., a subsidiary of LifeMap
Sciences, developing mobile health (mHealth) products; OrthoCyte
Corporation, developing therapies to treat orthopedic disorders,
diseases, and injuries; ReCyte Therapeutics, Inc., developing
therapies to treat a variety of cardiovascular and related ischemic
disorders; and Ascendance Biotechnology, Inc. which manufactures
and sells proprietary products and services that assay new drug
candidates for potential toxicity, including HepatoPac® and
HepatoMune®, and other products for use as research tools.
BioTime common stock is traded on the NYSE MKT and
TASE under the symbol BTX. For more information, please visit
www.biotimeinc.com or connect with the company
on Twitter, LinkedIn, Facebook, YouTube,
and Google+.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160201006085/en/
BioTime, Inc.Dan L. Lawrence,
510-775-0510dlawrence@biotimeinc.comorEVC Group, Inc.Michael
Polyviou, 646-445-4800mpolyviou@evcgroup.comorMedia Contact:Gotham
Communications, LLCBill Douglass,
646-504-0890bill@gothamcomm.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Apr 2023 to Apr 2024